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Health survey
Baseline
(n=36)
1-month
(n=36) P value
SF-36
Physical Component
Scale
35.3 9.5 38.110.6 0.24
Mental Component Scale 46.89.0 44.010.2 0.22
Cognitive assessment
MMSE 25.93.3 27.62.4 <0.001
Rouleau 8.31.3 8.22 0.27
CTT-1 76.220.8 7518.4 0.89
CTT-2 7917.8 8119.2 0.32
Cognistat 51 5.70.7 0.001
Functional assessment
DASI 17.39.7 17.39.8 0.97
Barthel Index 90.713.1 90.017.1 0.95
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Background: There are no direct comparisons between Transapical- Aortic Valve
Implantation (TA-AVI) and Transfemoral-Aortic Valve Implantation (TF-AVI).
Therefore, the aim of this propensity–matched study was to compare the short- and
mid-term outcomes of TA-AVI versus TF-AVI.
Methods: Data from 4 European centers were pooled and analyzed. To minimize
differences a propensity-score analysis was performed matching patients undergoing
TA-AVI and TF-AVI. Study endpoints were deﬁned according to the Valve Academic
Research Consortium-I at 30 days and 1 year. Primary endpoints of this study were
30-day all-cause mortality and mortality during follow-up.
Results: A total of 882 underwent TAVI of whom 793 patients TF-AVI (89.9%) and
89 patients (10.1%) TA-AVI. After propensity matching, 87 patients were identiﬁed in
each cohort. The logistic EuroSCORE was 25.7 (15.5 – 35.8) in the TF-AVI cohort
and 27.0 (20.1 – 34.0) in the TA-AVI cohort. TF-AVI was associated with a higher
frequency of major (16.1 vs. 5.7%, p¼0.029) and minor vascular complications (16.1
vs. 2.3%, p ¼ 0.002). In-hospital stay was signiﬁcantly longer in patients undergoing
TA-AVI (10.0 [6.5 – 13.5] vs. 7.0 [5.5 – 8.5], p<0.001). At 30 days, there was a trend
towards an increased risk of all-cause mortality in the TA-AVI group (16.1% vs.
6.9%, HR [95% C.I.]: 2.92 [0.82 – 10.46], p ¼ 0.09). During a median (IQR) follow-
up of 365 days (114 – 616 days), TA-AVI was associated with an increased mortality
(HR [95% C.I.]: 3.25 [1.11 – 9.50], p ¼ 0.03).
Conclusions: In institutions with a low volume of TA-AVI, TA-AVI is associated
with an increased risk of all-cause mortality and longer hospital stay but less vascular
complications in comparison to TF-AVI. The interaction between experience and type
of treatment on outcome requires further investigation before advocating one treat-
ment over the other.
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Background: TAVI is occasionally associated with stroke and silent cerebral
ischemia, which may affect cognitive and functional performance. Conversely, it is
suggested that improved systemic perfusion following the procedure may improve
patient cognitive function.
Methods: We performed a comprehensive prospective functional, cognitive and
quality of life (QOL) evaluation, in consecutive patients who underwent TAVI using
the CoreValve device (Medtronic Inc). The evaluation was performed at baseline and
one month after the procedure and included the short form 36 health survey (SF-36)
for quality of life assessment, Mini-Mental status examination (MMSE), Quantitative
clock drawing test (Rouleau), color trail test (CTT1 and CTT2), Cognistat evaluation,
Barthel index (BI) scoring and Duke Activity Status Index (DASI). All tests were
performed by an occupational therapist that specializes in cognitive function
assessment.
Results: A total of 36 patients completed the full pre and post evaluation. Mean age
was 82.24.2 years (52.8% men), 94.5% of patients had NYHA grade III/IV and
13.9% had prior stroke. After the procedure, all patients had improved their NYHA
functional status and valve hemodynamics. At 1 month there was a signiﬁcant
improvement in the MMSE and Cognistat evaluation (25.93.3 to 27.62.4,
p<0.001, 51 to 5.70.7 p¼0.001, respectively).
Conclusions: Our preliminary results of a comprehensive assessment of patients
undergoing TAVI indicate favorable results in both functional performances and
cognitive function early after the procedure.B220 JACC Vol 62/18/Suppl B j October 27–NovemberTCT-722
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Background: Percutaneous coronary intervention is associated with worse outcome
in diabetic patients. The outcomes of diabetes mellitus (DM) patients undergoing
surgical aortic valve replacement are poor compared to non-diabetic patients (ND).
The present study aimed to evaluate whether the presence of diabetes has an impact on
the outcome of patients undergoing transcatheter aortic valve replacement (TAVR).
Methods: All patients undergoing TAVR were included. A comparison among
baseline, procedural, and post-procedural outcomes was performed between DM and
ND patients.
Results: Out of 373 patients who underwent TAVR, 114 (30.5%) had DM while 259
(69.5%) did not. Most of the baseline and procedural characteristics were similar.
Society of Cardiothoracic Surgeons (STS) score did not differ between groups (DM
10.724.83 vs. ND 10.374.50; p¼0.511). No major differences were noted in
mortality rates at 30 days (DM 7.0% vs. ND 8.9%; p¼0.53) and at 1 year (DM 20%
vs. ND 20.6%; p¼0.891). However, the rates of major vascular complication and life
threatening bleeding were higher in the ND group (14.0% vs. 5.2%;p¼0.013; 10.5%
vs. 4.3%; p¼0.049, respectively), which translated into prolonged hospital stay (ND-
10.237.97 vs. DM 8.46.28 days; p¼0.018). Further, no outcome differences were
noted between DM patients treated with insulin (n¼38) versus those on oral/diet
therapy (n¼71). For comparison, our center's surgical data (2003-2012) for isolated
aortic valve replacement (DM n¼321 vs. ND n¼941) demonstrated that DM patients
used more blood products(786961 vs. 599859 ml; p¼0.001), had more post-
procedural renal failure (8.1% vs. 2.2%; p <0.005) and longer hospital stay (1111
vs. 98 days; p<0.001), although the mean STS score in this group was lower than in
the TAVR group (DM 5.36.3 vs. ND 3.14.3; p <0.001). These differences did not
translate to differences in in-hospital mortality.
Conclusions: Unlike with surgical aortic valve replacement, when disparities in
mortality exist between DM and ND even in intermediate-risk patients, the outcomes
of patients undergoing TAVR are mostly similar regardless of the presence of dia-
betes. TAVR should be considered as an alternative for surgery in suitable DM
patients.1, 2013 j TCT Abstracts/POSTER/Aortic Valve Disease and Treatment
